Please assess the completion status of the following clinical trial:

Trial Title: Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Untreated, stage IIIB with pleural effusion~* Untreated, Stage IV, non-small cell lung cancer~* Recurrent after surgery if no previous radiation therapy or chemotherapy were administered as part of their primary treatment, except for palliative radiotherapy~* 18 years of age or older~* ECOG PS 0, 1 or 2~* At Least one target lesion according to the RECIST Criteria~* Adequate organ and marrow function~Exclusion Criteria:~* Previous cancer history unless they have had curative treatment completed at least 5 years prior to entry.~* No previous radiotherapy, chemotherapy or immunotherapy for NSCLC, except for radiation therapy to the brain to control metastasis, bone to control pain, or lung to relieve bronchial obstruction.~* No radiation therapy for any previous cancer to more than 25% of bone marrow.~* Uncontrolled, intercurrent illness~* Non-study corticosteroids~* Pregnant women~* Peripheral neuropathy greater than grade 1~* Uncontrolled seizures, central nervous system disorders~* Major surgery within 4 weeks of the start of study treatment~* Lack of complete recovery from major surgery.~* Glaucoma~* Lack of physical integrity of upper gastrointestinal tract, inability to swallow tablets~* Severe acquired or hereditary immunodeficiency~* Patients with brain metastases must receive definitive treatment (radiation, surgery or both) and be clinically and radiologically stable for 4 weeks \& off corticosteroids for at least 2 weeks prior to randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 No Dex (Type: OTHER): No Dexamethasone
- 2 Dex (Type: EXPERIMENTAL): Dexamethasone

Based on this trial design, predict the completion outcome and termination type (if applicable).